HUTCHMED (China) (HCM) Cash & Current Investments (2014 - 2025)
HUTCHMED (China)'s (HCM) quarterly Cash & Current Investments came in at $175.8 million in Q4 2025, down 100.0% year-on-year from $107549.6 billion in Q4 2024, and down 87.12% on a QoQ basis from $1.4 billion in Q2 2025.
HUTCHMED (China) (HCM) Cash & Current Investments (2014 - 2025) Analysis & Trends
HUTCHMED (China) (HCM) has 12 years of Cash & Current Investments data on file, last reported at $175.8 million in Q4 2025.
- On a quarterly basis, Cash & Current Investments fell 100.0% year-over-year to $175.8 million in Q4 2025; TTM through Dec 2025 was $175.8 million, a 100.0% decrease from a year earlier, with the FY2025 full-year figure at $175.8 million, down 100.0% from the prior year.
- Cash & Current Investments for Q4 2025 stood at $175.8 million, down from $1.4 billion in the prior quarter.
- Over the last five years, Cash & Current Investments for HCM reached as high as $107549.6 billion in Q4 2024 and fell as low as $113433.7 in Q4 2023.
- Historically, Cash & Current Investments has averaged $9777.7 billion across 5 years, with a median of $802.5 million in 2024.
- Across the five-year window, Cash & Current Investments surged 94812718875.99% in 2024 and sank 100.0% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $129.9 million in 2021, then plunged by 37.89% to $80.7 million in 2022, then plunged by 99.86% to $113433.7 in 2023, then surged by 94812718875.99% to $107549.6 billion in 2024, then sank by 100.0% to $175.8 million in 2025.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $175.8 million in Q4 2025, $1.4 billion in Q2 2025, and $107549.6 billion in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - | - |
| 7 | Viatris | 20.23 Bn | 18.42 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 428.00 Mn |
| 10 | HUTCHMED (China) | 9.57 Bn | 9.39 Bn | - | 175.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 175.80 Mn |
| Jun 30, 2025 | 1.36 Bn |
| Dec 31, 2024 | 107,549.61 Bn |
| Jun 30, 2024 | 802.45 Mn |
| Dec 31, 2023 | 113,433.74 |
| Jun 30, 2023 | 856.17 Mn |
| Dec 31, 2022 | 80.67 Mn |
| Jun 30, 2022 | 826.20 Mn |
| Dec 31, 2021 | 129.88 Mn |
| Jun 30, 2021 | 950.45 Mn |
| Mar 31, 2021 | 396.07 Mn |
| Dec 31, 2020 | 435.18 Mn |
| Jun 30, 2020 | 281.01 Mn |
| Dec 31, 2019 | 217.17 Mn |
| Sep 30, 2019 | 201.58 Mn |
| Jun 30, 2019 | 237.29 Mn |
| Mar 31, 2019 | 271.86 Mn |
| Dec 31, 2018 | 300.95 Mn |
| Jun 30, 2018 | 322.49 Mn |
| Dec 31, 2017 | 358.30 Mn |